Small particle drug-eluting beads-transarterial chemoembolization combined with targeted therapy in the clinical treatment of unresectable liver cancer

doi:10.4251/wjgo.v16.i10.4157

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (462)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

HTML

301

Figures (1-1)

Tables (1-4)

Sum=411

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=35

Oct 15, 2024 (publication date) through Oct 19, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4157-4165
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4157

Full Size Figure Download Figure

Figure 1 Tumor response 1 month after surgery in the two groups and survival curve graph. A: Tumor response 1-month postoperatively in the two groups. ^aP < 0.05; B: Survival curve graph of overall survival in both groups; C: Survival curve graph of progression-free survival in both groups. CR: Complete response; DCR: Disease control rate; ORR: Objective response rate.

Citation: Qi JS, Zhao P, Zhao XB, Zhao YL, Guo YC. Small particle drug-eluting beads-transarterial chemoembolization combined with targeted therapy in the clinical treatment of unresectable liver cancer. World J Gastrointest Oncol 2024; 16(10): 4157-4165
URL: https://www.wjgnet.com/1948-5204/full/v16/i10/4157.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i10.4157